circCDYL2-GRB7-FAK complex plays a critical role in maintaining HER2 signaling, which contributes to trastuzumab resistance and circCDYL2 is a potential biomarker for trastuzumab-resistance in HER2+_C patients.
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.